New quadrivalent meningitis vaccine aims to shield China's youngest from deadly infection

NCT ID NCT07710872

Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This phase 3 study tests an investigational meningococcal conjugate vaccine in healthy infants and toddlers aged 2 to 23 months in China. The vaccine targets four serogroups of meningococcal bacteria (A, C, W, Y) that can cause meningitis and bloodstream infections. Researchers compare the new vaccine's safety and immune response to locally licensed vaccines, with participants receiving multiple doses and follow-up over several months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an investigational quadrivalent meningococcal conjugate vaccine (MenACYW conjugate vaccine)
What this could lead to
If successful, this vaccine could help protect infants and toddlers in China against four common types of meningococcal bacteria that cause serious infections like meningitis.
What could go wrong
This is a phase 3 trial, but results may differ in real-world use. The vaccine's effectiveness and safety are still being confirmed, and side effects like injection site reactions or fever are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.